Detalhe da pesquisa
1.
Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancer.
Gynecol Oncol
; 185: 128-137, 2024 Feb 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38412736
2.
Left Ventricular Ejection Fraction in Patients With Ovarian Cancer Treated With Avelumab, Pegylated Liposomal Doxorubicin, or Both.
Oncologist
; 28(10): e977-e980, 2023 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37665777
3.
Patient-reported outcomes of maintenance rucaparib in patients with recurrent ovarian carcinoma in ARIEL3, a phase III, randomized, placebo-controlled trial.
Gynecol Oncol
; 175: 1-7, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37262961
4.
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100.
Gynecol Oncol
; 178: 119-129, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37862791
5.
Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study.
Int J Gynecol Cancer
; 33(8): 1253-1259, 2023 08 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37072323
6.
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.
Lancet Oncol
; 23(7): 919-930, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35690073
7.
Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer.
Gynecol Oncol
; 166(2): 254-262, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35718565
8.
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.
Gynecol Oncol
; 167(3): 404-413, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36273926
9.
Data Set for the Reporting of Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma: Recommendations From the International Collaboration on Cancer Reporting (ICCR).
Int J Gynecol Pathol
; 41(Suppl 1): S119-S142, 2022 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36305537
10.
Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study.
Int J Gynecol Cancer
; 32(6): 761-768, 2022 06 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35086926
11.
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(9): 1275-1289, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34363762
12.
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
Lancet Oncol
; 22(7): 1034-1046, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34143970
13.
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 22(5): 620-631, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33743851
14.
Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
Lancet Oncol
; 22(2): 277-288, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33357510
15.
Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
Cancer
; 127(14): 2432-2441, 2021 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33740262
16.
Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response.
Br J Cancer
; 125(12): 1666-1676, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34663950
17.
Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer.
Gynecol Oncol
; 161(2): 496-501, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33637348
18.
Frontline Maintenance Treatment for Ovarian Cancer.
Curr Oncol Rep
; 23(8): 97, 2021 06 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34125335
19.
Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3.
Int J Gynecol Cancer
; 31(7): 949-958, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34103386
20.
Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial.
Lancet Oncol
; 21(7): 969-977, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32615110